22 min listen
Role of Immune Checkpoint Inhibitors in the Management of Metastatic NSCLC without Actionable Mutations with Dr Corey Langer
Role of Immune Checkpoint Inhibitors in the Management of Metastatic NSCLC without Actionable Mutations with Dr Corey Langer
ratings:
Length:
39 minutes
Released:
Jan 29, 2021
Format:
Podcast episode
Description
Dr Corey Langer from the Abramson Cancer Center at the University of Pennsylvania discusses recently published and emerging data on the role of immune checkpoint inhibitors in the treatment of metastatic non-small cell lung cancer without actionable mutations.
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNSCLCWT21)
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNSCLCWT21)
Released:
Jan 29, 2021
Format:
Podcast episode
Titles in the series (100)
Dr Tom Lynch on Adjuvant EGFR TKIs in Lung Cancer and COVID-19 in Seattle: Dr Tom Lynch comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. by Oncology Today with Dr Neil Love